Total
0
Shares
Algernon Pharmaceuticals (CSE:AGN)  to conduct DMT Stroke Program study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET)
  • KCSA is a fully integrated communications consultancy firm that will provide strategic support for Mindset's research of next-generation psychedelic compounds
  • Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines
  • Mindset Pharma Inc. (MSET) is up 1.85 per cent and is currently trading at $0.55 per share

KCSA Strategic Communications has signed an agreement to provide investor relations services to Mindset Pharma (MSET).

The agreement, effective May 15, has an initial term of six months.

KCSA is a fully integrated communications consultancy with a creative and strategic approach to public relations, investor relations and social media.

Mindset Pharma is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

KCSA will provide strategic support for this research by reaching out to potential investors and marketing the compound.

Jeffrey Goldberger, managing partner and principal of KCSA Strategic Communications commented,

"KCSA is excited to partner with the management team of Mindset to help increase investor awareness of this very exciting CNS-focused drug development company."

Jeffrey added,

"As a firm dedicated to supporting the medical psychedelics industry, KCSA is well versed in the sector and is confident the underlying science of psychedelic compounds holds great promise in treating a variety of psychiatric disorders."

The agreement may be terminated with 90 days' written notice by either party following the conclusion of the initial six-month term.

Mindset Pharma is a drug discovery and development company focused on creating psychedelic medicines to treat neurological and psychiatric disorders.

Mindset Pharma Inc. (MSET) is up 1.85 per cent and is trading at $0.55 per share as of 3:59 pm ET. 

More From The Market Herald
Clearmind Medicine (CSE:CMND) announces closing of private placement

" Clearmind Medicine (CSE:CMND) partners with The Hebrew University

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team. - The Market Herald Canada

" Negev Capital doubles down on Small Pharma (TSXV:DMT)

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).
PharmaTher (CSE:PHRM) added to the North American Psychedelics Index & the Horizons Psychedelic Stock Index ETF

" PharmaTher (CSE:PHRM) added to the North American Psychedelics Index & the Horizons Psychedelic Stock Index ETF

PharmaTher Holdings (PHRM) has been included in the North American Psychedelics Index.
Silo Wellness (CSE:SILO) debuts Marley One in collaboration with the Bob Marley family

" Psyched Wellness (CSE:PSYC) initiates a clinical sleep study

Psyched Wellness (PSYC) has initiated a clinical study of its AME-1 as a sleep-enhancing food supplement for self-declared insomniacs.